{"id":191121,"date":"2026-10-23T10:29:09","date_gmt":"2026-10-23T10:29:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/191121\/"},"modified":"2026-10-23T10:29:09","modified_gmt":"2026-10-23T10:29:09","slug":"exclusive-dr-reddys-rolls-out-new-generic-ozempic-brands-amid-obeda-supply-disruption","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/191121\/","title":{"rendered":"Exclusive-Dr Reddy&#8217;s rolls out new generic Ozempic brands amid Obeda supply disruption"},"content":{"rendered":"<p>HYDERABAD, Oct 23  \u2014  Dr Reddy&#8217;s Laboratories has expanded its portfolio of generic versions of Ozempic with two new brands, according to product \u200bphotographs and marketing materials reviewed by Reuters, after supply disruptions hit sales of its original Obeda injection in India&#8217;s fast-growing semaglutide market.<\/p>\n<p>Obeda Pro and Obeda Plus are made by a different manufacturer than the original \u200cObeda injectable, supplies of which were halted in July after Dr Reddy&#8217;s discovered an impurity in the active ingredient.<\/p>\n<p>Dr Reddy&#8217;s is likely to discontinue supplies \u2060of Obeda and instead focus on Obeda Pro and Obeda \u200bPlus, several distributors told Reuters.<\/p>\n<p>&#8220;The company said there were \u2060some technical issues with Obeda injectable, and they recalled stocks from us. They said they would instead supply Obeda \u200cPro,&#8221; a drug distributor said on \u200ccondition of anonymity as they were not authorized to speak to the media.<\/p>\n<p>The development and launch \u2060planning for products such as Obeda Pro and Obeda Plus were under \u2060way well before the July supply disruption issues, Dr Reddy&#8217;s said in response to a Reuters request for comment.<\/p>\n<p>&#8220;The presence of multiple semaglutide brands and manufacturing arrangements reflects the breadth of our portfolio strategy and should not be interpreted as evidence that one product was launched to replace another,&#8221; it said.<\/p>\n<p>Dr Reddy&#8217;s recalled Obeda injection in July &#8220;for technical evaluation,&#8221; according to a notice reviewed by Reuters. The company did not reply to a \u200cReuters question on whether the recall was related to the impurity. An oral version \u200bof the drug was not recalled.<\/p>\n<p>Dr Reddy&#8217;s launched Obeda \u2014 a generic version of Novo Nordisk&#8217;s diabetes drug \u2014 in India in March after semaglutide lost patent protection in the country, setting off a race among domestic pharma companies to launch lower-cost versions of the drug.<\/p>\n<p>Semaglutide, which suppresses appetite, is also the active ingredient in Novo&#8217;s blockbuster weight-loss drug Wegovy.<\/p>\n<p>Obeda Plus and Obeda Pro are available in different dose strengths, just like Ozempic and Wegovy.<\/p>\n<p>Research firm Pharmarack estimated in March that the domestic market for semaglutide drugs will grow to 80 billion rupees ($843.99 million) by 2030.<\/p>\n<p>Dr \u200bReddy&#8217;s said in July that supplies of Obeda injections would be unavailable until November. Analysts warned at the time that the company risked \u200closing market share \u200cin India&#8217;s increasingly competitive \u2060semaglutide market if supplies were not restored quickly. Dr Reddy&#8217;s did not reply to a question on whether it had resolved the impurity issue.<\/p>\n<p>Packaging materials reviewed by Reuters showed Obeda was manufactured by contract manufacturer OneSource Specialty Pharma. Obeda Pro and Obeda Plus, which began appearing in the market in late July according to supply invoices reviewed by Reuters, are manufactured \u200cby Hetero Labs.<\/p>\n<p>Hetero Labs and OneSource Specialty \u200bPharma did not respond to requests for comment.<\/p>\n<p>Dr Reddy&#8217;s sold about \u200c442,000 units of generic semaglutide through \u2060September in India, according \u200bto research firm Pharmarack. By comparison, India&#8217;s largest drugmaker Sun Pharma sold 151,000 semaglutide units.<\/p>\n<p>($1 = 94.7875 Indian rupees)<\/p>\n<p>(Reporting by Rishika Sadam; Editing \u200bby Kevin Buckland)<\/p>\n","protected":false},"excerpt":{"rendered":"HYDERABAD, Oct 23 \u2014 Dr Reddy&#8217;s Laboratories has expanded its portfolio of generic versions of Ozempic with two&hellip;\n","protected":false},"author":2,"featured_media":191122,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[1298,6402,6403,1343,33,38,272,6127,6404,135,2410,5423,6405,1646],"class_list":["post-191121","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-cars","tag-classifieds","tag-homes","tag-jobs","tag-local","tag-news","tag-novo-nordisk","tag-radio","tag-salt-lake","tag-sports","tag-television","tag-traffic","tag-utah","tag-weather"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117489760066923541","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/191121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=191121"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/191121\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/191122"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=191121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=191121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=191121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}